The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A system may include an inhaler (100) and an external device (904). The inhaler may include a main body (104) having a mouthpiece (106), medicament, and an electronics module (120). The electronics module may include a processor (1026), memory (1030), a sensor (1027), a switch (130), and a wireless communication circuit (129). The processor may generate a dose record in response to a dosing event. The dosing event may be an actuation of the switch (130) or measurements received by the sensor (1027). The processor (1026) may store the first dose record in memory and cause the wireless communication circuit (129) to transmit advertising data. The advertising data may include a dose record indicator that indicates that one or more dose records are stored in the memory (1030) of the electronics module (120). The external device (904) may receive the advertising data and determine, based on the advertising data, whether the inhaler (100) includes records not stored on the external device.
A system may be configured for sending a Uniform Resource Locator (URL) request based on a location of an external device (502). An inhaler (100) may include medicament, an electronics module (120), and/or a Quick Response (QR) code (160). An external device may determine a URL and/or a medicament type of the inhaler (100) based on the QR code (160). The external device may send an indication of the medicament type and/or a location indication to a server that hosts the URL. In response, the external device (502) may receive an application store URL that is specific to the medicament type and/or the location of the external device. The external device may send a request to the application store URL to download software that is specific to the inhaler (100) and/or the medicament type of the inhaler. The application store URL may be specific to a country that the external device is located.
G06K 7/14 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation using light without selection of wavelength, e.g. sensing reflected white light
Provided is a system comprising an inhaler. The inhaler comprises a use determination system. The use determination system is configured to determine a parameter relating to airflow during a use of the inhaler by a subject. The use determination system also assigns a time to the use. The system also comprises a user interface, and a processing module. The processing module is configured to determine inhalation information from the parameter, and control the user interface to issue a notification that the inhalation information is available. The notification is issued at a notification time. The processing module is configured to implement a deliberate time delay such that the notification time is delayed relative to the time assigned to the use.
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61M 16/14 - Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
G06F 3/0488 - Interaction techniques based on graphical user interfaces [GUI] using specific features provided by the input device, e.g. functions controlled by the rotation of a mouse with dual sensing arrangements, or of the nature of the input device, e.g. tap gestures based on pressure sensed by a digitiser using a touch-screen or digitiser, e.g. input of commands through traced gestures
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; Pharmaceutical preparations for the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders;; Contraceptive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; Pharmaceutical preparations for the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; Contraceptive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; Pharmaceutical preparations for the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders;; Contraceptive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; Pharmaceutical preparations for the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; Contraceptive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; Pharmaceutical preparations for the treatment of for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; Contraceptive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment and prevention of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; Pharmaceutical preparations for the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; Contraceptive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical products for treating respiratory diseases and asthma
A breath actuated metered dose inhaler may comprise a canister fire system configured to fire a medicament containing canister in response to patient inhalation. The canister fire system may comprise a pneumatic force holding unit and having a rest configuration in which a metering valve of the canister is in a refill configuration;
a prepared configuration in which a canister actuation force is retained by the pneumatic force holding unit and the canister fire system is actuatable by patient inhalation induced airflow; and a fire configuration in which the metering valve is in a dose delivery position. When in the prepared configuration, the force retained by the pneumatic force holding unit may be reduced by less than about 6% over a period of 5 minutes, preferably less than about 3% over a period of 5 minutes.
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61M 16/20 - Valves specially adapted to medical respiratory devices
Disclosed is a dry powder inhaler for delivering medicament from at least one blister pack, each blister pack having a plurality of spaced-apart blister pockets containing doses of the medicament. The inhaler comprises: a housing for accommodating unused and used portions of the at least one blister pack together with a dispensing mechanism for simultaneously opening at least two blister pockets at a time; and a manifold component through which air can be drawn in use of the inhaler. The manifold component comprises: first and second air inlet openings for receiving external air; a first air outlet opening for providing the external air to a first opened blister pocket and a first medicament inlet opening for receiving air-entrained medicament from the first opened blister pocket, the first air outlet opening and the first medicament inlet opening being arranged side-by-side to enable simultaneous communication with the first opened blister pocket; a second air outlet opening for providing the external air to a second opened blister pocket and a second medicament inlet opening for receiving air-entrained medicament from the second opened blister pocket, the second air outlet opening and the second medicament inlet opening being arranged side-by-side to enable simultaneous communication with the second opened blister pocket; and a medicament outlet opening for delivery of the air-entrained medicament from the first and second opened blister pockets to the user, the first and second medicament inlet openings being fluidly connected to the medicament outlet opening by a medicament delivery conduit formed in the manifold component. The first and second air inlet openings are fluidly connected to the first and second air outlet openings by respective first and second air conduits in the manifold component, wherein the air conduits are separately provided so that the external air from each of the first and second air inlet openings does not mix with the external air from the other of the first and second air inlet openings before reaching the first and second opened blister pockets.
This invention relates to a method for the treatment of asthma comprising pro re nata (PRN) administration of a fixed-dose dry powder inhalation composition comprising fluticasone propionate and albuterol sulfate as a rescue medication in patients aged from ≥4 years to <18 years. Also provided is a fixed-dose dry powder inhalation composition and dry powder inhaler for performing the method of the present invention.
This invention relates to a method for the treatment of asthma comprising pro re nata (PRN) administration of a fixed-dose dry powder inhalation composition comprising fluticasone propionate and albuterol sulfate as a rescue medication in patients aged from ≥4 years, wherein the fluticasone propionate is administered at a delivered dose of 22-59 mcg per inhalation and the albuterol sulfate is administered at a delivered dose of 92-124 mcg per inhalation and wherein the treatment provides one or more of prolonging the time to first severe clinical asthma exacerbation when compared to albuterol sulfate rescue treatment, reducing the total annualized systemic corticosteroid (SCS) exposure when compared to albuterol sulfate rescue treatment, and reducing the annualized severe clinical asthma exacerbation rate, when compared to albuterol sulfate rescue treatment.. Also provided is a fixed-dose dry powder inhalation composition and dry powder inhaler for performing the method of the present invention.
An inhaler includes a main body having a canister housing, a medicament canister retained in a central outlet port of the canister housing, and a dose counter having an actuation member for operation by movement of the medicament canister. The canister housing has an inner wall, and a first inner wall canister support formation extending inwardly from a main surface of the inner wall. The canister housing has a longitudinal axis X which passes through the center of the central outlet port. The first inner wall canister support formation, the actuation member, and the central outlet port lie in a common plane coincident with the longitudinal axis X such that the first inner wall canister support formation protects against unwanted actuation of the dose counter by reducing rocking of the medicament canister relative to the main body of the inhaler.
Provided is a blister pack for a dry powder inhaler, which dry powder inhaler is configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament. The first and second powder medicaments are contained within blister pockets defined in a strip. A series of blister pockets is defined in the strip, which series extends linearly along the length of the strip. The first and second powder medicaments are contained in blister pockets, e.g. respective blister pockets, of the series. Alternatively or additionally, each of the blister pockets is elongated such as to have a largest dimension parallel with the length of the strip. These measures, either individually or in combination, enable minimizing of the width of the strip in spite of the strip accommodating both the first and second powder medicaments. This, in turn, may enable the depth/thickness of the dry powder inhaler to be minimized, and/or additional space to be provided inside the dry powder inhaler for accommodating, for example, use detection and wireless connectivity electronics for sending use detection data to an external device, such as a smartphone.
The introduction of electronics into a drug delivery device may introduce certain technical challenges, such as durability, electro-mechanical integration, and drug delivery performance. The present disclosure provides solutions for inclusion of an electronics module with an inhaler. For example, heat stakes may be used to secure a printed circuit board (PCB) to an electronics module's housing. Also for example, a slider may be used to transfer vertical movement of an inhaler's yoke to an electronics module's switch. Also for example, certain seals may be used when interfacing the electronics module to other portions of the device's housing to achieve a desired performance.
An injection device is provided with embodiments of an improved dial down mechanisms. In one embodiment, the injection device may include a housing, a dial member configured to be rotated to set a dose of medicament, a drive sleeve configured to be rotated by the dial member, a dial sleeve disposed around the drive sleeve, a torsion spring having a first end fixed relative to the housing and a second end fixed relative to the drive sleeve and/or the dial sleeve, and a clutch ring configured to engage the dial sleeve so as to selectively resist rotation of the dial sleeve. Rotation of the drive sleeve may be configured to longitudinally translate the dial sleeve relative to the clutch ring to enable rotation of the drive sleeve during rotation of the dial member.
Provided is a system (10) for determining a probability of an asthma exacerbation in a subject. The system comprises an inhaler (100) for delivering a rescue medicament to the subject. The inhaler has a use-detection system (12B) configured to determine a rescue inhalation performed by the subject using the first inhaler. A sensor system (12A) is configured to measure a parameter relating to airflow during the rescue inhalation. The system further comprises a processor (14) configured to determine a number of the rescue inhalations during a first time period, and receive the parameter measured for at least some of the rescue inhalations. The processor determines, using a weighted model, the probability of the asthma exacerbation based on the number of rescue inhalations and the parameters. The model is weighted such that the number of rescue inhalations is more significant in the probability determination than the parameters.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/08 - Measuring devices for evaluating the respiratory organs
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Provided is a system for determining a probability of a respiratory disease exacerbation in a subject. The system comprises an inhaler arrangement for delivering a medicament to the subject. The medicament may be a rescue medicament and/or a maintenance medicament. The inhaler arrangement has a use-detection system configured to determine an inhalation performed by the subject using the inhaler arrangement. A sensor system is configured to measure a parameter relating to airflow during the inhalation. A user interface enables user-input of an indication of a status of the respiratory disease being experienced by the subject. A processor is configured to determine the probability of the respiratory disease exacerbation based on the recorded inhalation(s) from the use-detection system, the parameter(s) received from the sensor system, and the indication received from the user interface. Further provided is a method for determining the probability of a respiratory disease exacerbation in a subject.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/08 - Measuring devices for evaluating the respiratory organs
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A system may be configured for determining risk of an asthma exacerbation in a patient with non-eosinophilic asthma (NEA). The system may receive patient data for a patient. The patient data may comprise diagnostic data relating to the patient, laboratory data relating to the patient, pharmaceutical data relating to the patient, and procedure data relating to the patient. The system may also apply a trained model to the patient data to determine risk of an asthma exacerbation of the patient. The system may further generate a notification, via a display device, indicating the risk of the asthma exacerbation of the patient.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
An electronic module for a medical device such as an inhaler is disclosed, the electronic module comprising a printed circuit board, and a damper configured to dampen energy transfer to and/or from a battery when a battery is connected to the electronic module and the electronic module is exposed to mechanical shock.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
H05K 1/18 - Printed circuits structurally associated with non-printed electric components
Provided is a method for generating an assessment of a respiratory disease in a subject at a current point in time. The method comprises determining a baseline statistic relating to usage of an inhaler in a baseline period. The inhaler is configured to deliver a rescue medicament to the subject, and has a use determination system configured to determine usage of the inhaler by the subject. The method also comprises determining a current statistic relating to usage of the inhaler in a current period containing the current point in time. The method further comprises generating a comparator variable. Generating the comparator variable comprises comparing the current statistic and the baseline statistic. The assessment of the respiratory disease is based on the comparator variable.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A system may include a mobile application residing on an external device and an inhalation device. The inhalation device may include a mouthpiece, a mouthpiece cover, medicament, and an electronics module comprising a processor. The inhalation device may be configured to both prepare a dose of medicament for delivery to a user and cause the processor to transition between power states when the mouthpiece cover is moved from a closed position to an open position to expose the mouthpiece. The electronics module or the mobile application may be configured to generate usage events based on usage of the inhalation device by the user. The electronics module may also include a pressure sensor, and the electronics module or the mobile application may be configured to determine whether a usage event is a good inhalation event, a fair inhalation event, or a no inhalation event based on feedback from the pressure sensor.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
An inhaler may include a housing that comprises a mouthpiece, a medication canister, and an airflow channel formed between an air inlet and the mouthpiece. The inhaler may also include a pressure sensor configured to measure pressure (e.g., or alternatively, an acoustic sensor to measure acoustic sound waves). The pressure sensor may be attached to the medicament canister of the inhaler. The pressure sensor may be configured to be in a first position relative to the airflow channel when the medication canister is not actuated, and in a second position relative to the airflow channel when the medication canister is in an actuated position. The inhaler may also include a processor that is configured to receive pressure measurements from the pressure sensor, and detect whether an inhalation occurs prior the medication canister being depressed to release medication based on the pressure measurements (e.g., only the pressure measurements).
Systems, methods, and instrumentalities are disclosed herein for wireless communication across multiple devices. The devices may include, for example, one or more smart pads, an inhaler associated with a patient, a mobile device associated with the patient, a smart home device, and/or the like. The devices may communicate using different wireless communication protocols, for example, near-field communication (NFC), Bluetooth, Bluetooth Low Energy (BLE), Wi-Fi, cellular communication, etc. The inhaler may be placed on one of the smart pads, which may store a location event and/or a timestamp in memory. Each of the smart pads may be associated with a respective geofenced area. The smart home device may determine that the mobile device has left the geofenced area while the smart pad is located on one of the smart pads. The smart home device may cause the mobile device to notify the patient that the inhaler is on the smart pad.
G16H 40/00 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices
An inhaler housing (14) for an inhaler (10) for inhaling inhalable substances, the inhaler having: a body (14) and a dose counter (24) with a return spring (28), wherein a distinct guide surface (162) is provided for guiding the end of the return spring into a recess (152), the distinct guide surface being wider than an entrance mouth (160) of the recess, a dose counter chamber (22) being provided which is separated from a tubular interior space (182) of the inhaler by a barrier (180), the barrier including a stepped upper wall area (184) including at least three steps (186, 188, 190, 192) at different levels, the inhaler having a valve stem block (62) having an inner bore and a valve stem block having a seal (224) in the inner bore with a second diameter which is smaller than a first diameter of the inner bore, the inhaler having a canister (150) being adapted to move during operation between 1 and 4 mm, a drive being arranged to apply a firing force of between 15N and 60N of force to the canister at a position of the canister relative to a valve stem (54) at which the canister fires.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61M 15/08 - Inhaling devices inserted into the nose
A61P 11/00 - Drugs for disorders of the respiratory system
Provided is a pharmaceutical composition comprising an oral corticosteroid for use in post-exacerbation treatment of a respiratory disease in a subject, which post-exacerbation treatment includes an initial dose of the oral corticosteroid. The post-exacerbation treatment being continued until fulfilment of an inhalation parameter criterion by one or more post-exacerbation inhalations performed by the subject with at least one inhaler and/or fulfilment of a rescue inhaler usage criterion relating to post-exacerbation usage of a rescue inhaler configured to deliver a rescue medicament to the subject, at which point the dose of the oral corticosteroid is changed from the initial dose. Further provided are systems and methods for determining whether the inhalation parameter criterion is fulfilled and for comparing a post-exacerbation value of an inhalation parameter to a baseline value of the inhalation parameter.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A dry powder inhaler for delivering medicament from at least one medicament carrier having a plurality of spaced-apart medicament doses. The inhaler includes a housing having regions for accommodating unused and used portions of the medicament carrier, a mouthpiece component extending from the housing and through which a user is able to inhale, a dispensing mechanism arranged in the housing for moving a medicament dose of the medicament carrier to the dispensing position, and a mouthpiece cover being rotatably connected to the housing for sequential movement about a rotation axis from a first position in which the mouthpiece component is completely covered to a second position in which the mouthpiece component is completely covered, and from the second position to a third position in which the mouthpiece component is completely uncovered, the second position being between the first and third positions.
Disclosed is a dry powder inhaler for delivering medicament from at least one blister pack, each blister pack having a plurality of spaced-apart blister pockets containing doses of the medicament. The inhaler comprises: a housing for accommodating unused and used portions of the at least one blister pack together with a dispensing mechanism for simultaneously opening at least two blister pockets at a time; and a manifold component through which air can be drawn in use of the inhaler. The manifold component comprises: first and second air inlet openings for receiving external air a first air outlet opening for providing the external air to a first opened blister pocket and a first medicament inlet opening for receiving air-entrained medicament from the first opened blister pocket, the first air outlet opening and the first medicament inlet opening being arranged side-by-side to enable simultaneous communication with the first opened blister pocket; a second air outlet opening for providing the external air to a second opened blister pocket and a second medicament inlet opening for receiving air-entrained medicament from the second opened blister pocket, the second air outlet opening and the second medicament inlet opening being arranged side-by-side to enable simultaneous communication with the second opened blister pocket; and a medicament outlet opening for delivery of the air-entrained medicament from the first and second opened blister pockets to the user, the first and second medicament inlet openings being fluidly connected to the medicament outlet opening by a medicament delivery conduit formed in the manifold component. The first and second air inlet openings are fluidly connected to the first and second air outlet openings by respective first and second air conduits in the manifold component, wherein the air conduits are separately provided so that the external air from each of the first and second air inlet openings does not mix with the external air from the other of the first and second air inlet openings before reaching the first and second opened blister pockets.
A system may be configured for sending a Uniform Resource Locator (URL) request based on a location of an external device (502). An inhaler (100) may include medicament, an electronics module (120), and/or a Quick Response (QR) code (160). An external device may determine a URL and/or a medicament type of the inhaler (100) based on the QR code (160). The external device may send an indication of the medicament type and/or a location indication to a server that hosts the URL. In response, the external device (502) may receive an application store URL that is specific to the medicament type and/or the location of the external device. The external device may send a request to the application store URL to download software that is specific to the inhaler (100) and/or the medicament type of the inhaler. The application store URL may be specific to a country that the external device is located.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Provided is a system comprising an inhaler. The inhaler comprises a use determination system. The use determination system is configured to determine at least one first value of a usage parameter relating to use of the inhaler. A processing module is configured to receive the at least one first value. The processing module is also configured to receive a second value indicative of whether the subject is also suffering from a viral respiratory infection. The processing module then determines the level of acute risk based on the at least one first value and the second value. Also provided is a system for determining a probability that a subject having a chronic respiratory disease also has a severe acute respiratory syndrome. The system comprises a first inhaler for delivering a rescue medicament prescribed for the chronic respiratory disease. The first inhaler has a use determination system configured to determine a rescue inhalation performed by the subject using the first inhaler. The system optionally includes a second inhaler for delivering a maintenance medicament to the subject during a routine inhalation A sensor system is configured to measure a parameter relating to airflow during the rescue inhalation and/or during the routine inhalation, when the second inhaler is included in the system. The system further comprises a processor configured to determine a number of the rescue inhalations during a first time period, and receive the parameter measured for at least some of the rescue and/or routine inhalations. The processor then determines the probability of the subject having the severe acute respiratory syndrome based on the number of rescue inhalations and the parameters. Further provided is a method for determining the probability of an asthma exacerbation in a subject, which method employs the weighted model.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
Provided is a system for providing an output for warning of a respiratory disease exacerbation in a subject. The system comprises a first inhaler for delivering a rescue medicament to the subject. The system optionally includes a second inhaler for delivering a maintenance medicament to the subject during a routine inhalation. A sensor system is configured to measure a parameter relating to airflow during the rescue inhalation and/or during the routine inhalation, when the second inhaler is included in the system. The system further comprises a processing module configured to monitor a frequency of the determined rescue inhalations. The processing module also monitors the parameter as a function of time. The processing module is further configured to provide the output for warning of a respiratory disease exacerbation if the parameter as a function of time is indicative of the lung condition of the subject deteriorating over a first time period, and the frequency of the determined rescue inhalations is higher during a second time period than during the first time period, the second time period being subsequent to the first time period. Further provided is a method for providing an output for warning of a respiratory disease exacerbation in a subject.
A system may include an inhaler (100) and an external device (904). The inhaler may include a main body (104) having a mouthpiece (106), medicament, and an electronics module (120). The electronics module may include a processor (1026), memory (1030), a sensor (1027), a switch (130), and a wireless communication circuit (129). The processor may generate a dose record in response to a dosing event. The dosing event may be an actuation of the switch (130) or measurements received by the sensor (1027). The processor (1026) may store the first dose record in memory and cause the wireless communication circuit (129) to transmit advertising data. The advertising data may include a dose record indicator that indicates that one or more dose records are stored in the memory (1030) of the electronics module (120). The external device (904) may receive the advertising data and determine, based on the advertising data, whether the inhaler (100) includes records not stored on the external device.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.
A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
A61K 9/00 - Medicinal preparations characterised by special physical form
A dry powder inhaler for delivering medicament from at least one medicament carrier having a plurality of spaced-apart medicament doses. The inhaler includes a housing having regions for accommodating unused and used portions of the medicament carrier, a mouthpiece component extending from the housing and through which a user is able to inhale, a dispensing mechanism arranged in the housing for moving a medicament dose of the medicament carrier to the dispensing position, and a mouthpiece cover being rotatably connected to the housing for sequential movement about a rotation axis from a first position in which the mouthpiece component is completely covered to a second position in which the mouthpiece component is completely covered, and from the second position to a third position in which the mouthpiece component is completely uncovered, the second position being between the first and third positions.
An inhalation device may include a canister elongate along a longitudinal axis, the canister containing medicament. The inhalation device may also include a movable inner housing that is configured to move with the canister when the medication canister is moved to administer a dose of medicament. The inhalation device may include an electronics module comprising a processor, a power supply, a sensor, and a plurality of contact pads. Further, the inhalation device may include a switch contact affixed to the moveable inner housing. In response to movement of the movable inner housing, the switch contact may be configured to move from a first position where the switch contact is not contacting the plurality contact pads to a second position where the switch contact is contacting at least one of the plurality of contact pads to change a power state of one or more of the processor and sensor.
Disclosed are dry powder inhalers for delivering medicament to a user from a blister pack, the blister pack having a plurality of spaced-apart blister pockets containing doses of the medicament. The inhalers comprise: a housing for accommodating unused and used portions of the blister pack together with a dispensing mechanism for selectively opening the blister pockets; and a manifold component through which air can be drawn in use of the inhaler. The manifold component comprises: a primary air inlet opening for receiving first external air; an air outlet opening for providing the external air from the primary air inlet opening into an opened blister pocket, the primary air inlet opening being fluidly connected to the air outlet opening by a primary air delivery conduit formed in the manifold component; a medicament inlet opening for receiving air-entrained medicament from the opened blister pocket, the air outlet opening and the medicament inlet opening being arranged side-by-side to enable simultaneous communication with the opened blister pocket; and a medicament outlet opening for delivery of the air-entrained medicament from the opened blister pocket to the user, the medicament inlet opening being fluidly connected to the medicament outlet opening by a medicament delivery conduit formed in the manifold component. The disclosed inhalers embodiments provide a variety of improvements to the design of the manifold component.
Disclosed is a dry powder inhaler for delivering medicament from at least one blister pack, each blister pack having a plurality of spaced-apart blister pockets containing doses of the medicament. The inhaler comprises: a housing for accommodating unused and used portions of the at least one blister pack together with a dispensing mechanism for simultaneously opening at least two blister pockets at a time; and a manifold component through which air can be drawn in use of the inhaler.
Provided is a blister pack for a dry powder inhaler, which dry powder inhaler is configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament. The first and second powder medicaments are contained within blister pockets defined in a strip. A series of blister pockets is defined in the strip, which series extends linearly along the length of the strip. The first and second powder medicaments are contained in blister pockets, e.g. respective blister pockets, of the series. Alternatively or additionally, each of the blister pockets is elongated such as to have a largest dimension parallel with the length of the strip. These measures, either individually or in combination, enable minimizing of the width of the strip in spite of the strip accommodating both the first and second powder medicaments. This, in turn, may enable the depth/thickness of the dry powder inhaler to be minimized, and/or additional space to be provided inside the dry powder inhaler for accommodating, for example, use detection and wireless connectivity electronics for sending use detection data to an external device, such as a smartphone.
Disclosed is a dry powder inhaler for delivering medicament from at least one blister pack, each blister pack having a plurality of spaced-apart blister pockets containing doses of the medicament. The inhaler comprises: a housing for accommodating unused and used portions of the at least one blister pack together with a dispensing mechanism for simultaneously opening at least two blister pockets at a time; and a manifold component through which air can be drawn in use of the inhaler. The manifold component comprises: first and second air inlet openings for receiving external air a first air outlet opening for providing the external air to a first opened blister pocket and a first medicament inlet opening for receiving air-entrained medicament from the first opened blister pocket, the first air outlet opening and the first medicament inlet opening being arranged side-by-side to enable simultaneous communication with the first opened blister pocket; a second air outlet opening for providing the external air to a second opened blister pocket and a second medicament inlet opening for receiving air-entrained medicament from the second opened blister pocket, the second air outlet opening and the second medicament inlet opening being arranged side-by-side to enable simultaneous communication with the second opened blister pocket; and a medicament outlet opening for delivery of the air-entrained medicament from the first and second opened blister pockets to the user, the first and second medicament inlet openings being fluidly connected to the medicament outlet opening by a medicament delivery conduit formed in the manifold component. The first and second air inlet openings are fluidly connected to the first and second air outlet openings by respective first and second air conduits in the manifold component, wherein the air conduits are separately provided so that the external air from each of the first and second air inlet openings does not mix with the external air from the other of the first and second air inlet openings before reaching the first and second opened blister pockets.
Disclosed are dry powder inhalers for delivering medicament to a user from a blister pack, the blister pack having a plurality of spaced-apart blister pockets containing doses of the medicament. The inhalers comprise: a housing for accommodating unused and used portions of the blister pack together with a dispensing mechanism for selectively opening the blister pockets; and a manifold component through which air can be drawn in use of the inhaler. The manifold component comprises: a primary air inlet opening for receiving first external air; an air outlet opening for providing the external air from the primary air inlet opening into an opened blister pocket, the primary air inlet opening being fluidly connected to the air outlet opening by a primary air delivery conduit formed in the manifold component; a medicament inlet opening for receiving air-entrained medicament from the opened blister pocket, the air outlet opening and the medicament inlet opening being arranged side-by-side to enable simultaneous communication with the opened blister pocket; and a medicament outlet opening for delivery of the air-entrained medicament from the opened blister pocket to the user, the medicament inlet opening being fluidly connected to the medicament outlet opening by a medicament delivery conduit formed in the manifold component. The disclosed inhalers embodiments provide a variety of improvements to the design of the manifold component.
A system may include an external device and an inhaler. The external device may include a processor, a communication circuit, and memory. The inhaler may include a mouthpiece, medicament, a mechanical dose counter, and an electronics module comprising a processor and a communication circuit. The electronics module may record a dosing event when the inhaler is actuated, such as when the mouthpiece cover is opened, and send a signal indicating the dosing event to the external device. The external device may receive a mechanical dose reading of the mechanical dose counter, determine an electronic dose reading based on the signal indicating the dosing event, determine that a discrepancy between the mechanical dose reading and the electronic dose reading exceeds a threshold, and notify the user of the discrepancy, for example, by providing a notification to the user by way of a mobile application residing on the external device.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
Provided is a dry powder inhaler (1) for delivering medicament from at least one medicament carrier (201) having a plurality of spaced-apart medicament doses. The inhaler comprises: a housing (3) having regions for accommodating unused and used portions of the medicament carrier; a mouthpiece component (5) extending from the housing and through which a user is able to inhale; a manifold (25) arranged in the housing and defining at least part of an air flow path extending from an air inlet to the mouthpiece, the manifold further defining a dispensing position for the medicament carrier; a dispensing mechanism arranged in the housing for moving a medicament dose of the medicament carrier to the dispensing position and for placing the medicament dose in fluid communication with the air flow path ready for inhalation by the user; and a mouthpiece cover (7) being rotatably connected to the housing for sequential movement about a rotation axis from a first position in which the mouthpiece component is completely covered to a second position in which the mouthpiece component is completely covered, and from the second position to a third position in which the mouthpiece component is completely uncovered. The mouthpiece cover is coupled to the dispensing mechanism such that movement of the mouthpiece cover drives the dispensing mechanism, wherein movement of the mouthpiece cover from the second position to the third position causes a medicament dose of the medicament carrier to be moved to the dispensing position, but movement of the mouthpiece cover from the first position to the second position does not causes the medicament dose to be moved. Also provided are arrangements in which the coupling of the mouthpiece cover to the dispensing mechanism is arranged to be non-linear, such that movement of the mouthpiece cover from a first position to a second position causes the medicament dose to be moved with a first movement ratio, and movement of the mouthpiece cover from the second position to a third position causes the medicament dose to be moved with a second movement ratio which is different to the first movement ratio.
Provided is a system comprising at least one inhaler. Each of the at least one inhaler comprises a use determination system configured to determine at least one value of a usage parameter relating to use of the respective inhaler by a subject. The system further comprises a user interface and a processing module. The user interface is configured to enable user-inputting of an indication of a status of a respiratory disease being experienced by the subject. The processing module is configured to control the user interface to issue a prompt to input the indication based on the at least one value.
A nasal inhaler for the inhalation of inhalable substances comprise: a canister having an interior reservoir containing pressurised inhalable substances including fluid; a metering valve including a metering chamber and a valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir, the interior reservoir being arranged for orientation above the metering chamber whereby gas located within the metering chamber is replaced with liquid from the interior reservoir.
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61M 15/08 - Inhaling devices inserted into the nose
An inhaler (10) has a main body for accommodating a medicament reservoir (84), a canister fire system for moving a canister (50) to release a dose in response to air flow, a cap housing (12) for enclosing the canister fire system and canister within an interior chamber defined by the main body (14) and a cap housing, wherein a lock system (250) is provided for locking the cap housing on the main body.
A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 9/00 - Medicinal preparations characterised by special physical form
B65D 41/04 - Threaded or like caps or cap-like covers secured by rotation
B65D 55/16 - Devices preventing loss of removable closure members
Provided is a system including a plurality of inhalers that each include a processor configured to determine a value of a usage parameter relating to use of the respective first inhaler, encrypt data based on the value, and transmit the encrypted data. At least two of the inhalers include different medicament, such as a rescue medicament and a maintenance medicament. The system includes an external device that includes a processor configured to distinguish between the encrypted data of each respective inhaler, determine respective usage information relating to each of the distinct types of medicament based on the respective encrypted data, and control a user interface (e.g., of the external device) to communicate the usage information related to each inhaler and/or each respective type of medicament.
G06K 7/14 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation using light without selection of wavelength, e.g. sensing reflected white light
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
Provided is a method for generating an assessment of a respiratory disease in a subject at a current point in time. The method comprises determining a baseline statistic relating to usage of an inhaler in a baseline period. The inhaler is configured to deliver a rescue medicament to the subject, and has a use determination system configured to determine usage of the inhaler by the subject. The method also comprises determining a current statistic relating to usage of the inhaler in a current period containing the current point in time. The method further comprises generating a comparator variable. Generating the comparator variable comprises comparing the current statistic and the baseline statistic. The assessment of the respiratory disease is based on the comparator variable.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Provided is a pharmaceutical composition comprising an oral corticosteroid for use in post-exacerbation treatment of a respiratory disease in a subject, which post-exacerbation treatment includes an initial dose of the oral corticosteroid. The post-exacerbation treatment being continued until fulfilment of an inhalation parameter criterion by one or more post-exacerbation inhalations performed by the subject with at least one inhaler and/or fulfilment of a rescue inhaler usage criterion relating to post-exacerbation usage of a rescue inhaler configured to deliver a rescue medicament to the subject, at which point the dose of the oral corticosteroid is changed from the initial dose. Further provided are systems and methods for determining whether the inhalation parameter criterion is fulfilled and for comparing a post-exacerbation value of an inhalation parameter to a baseline value of the inhalation parameter.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
A61P 11/00 - Drugs for disorders of the respiratory system
Provided is a system (10) for determining a probability of an asthma exacerbation in a subject. The system comprises an inhaler (100) for delivering a rescue medicament to the subject. The inhaler has a use-detection system (12B) configured to determine a rescue inhalation performed by the subject using the first inhaler. A sensor system (12A) is configured to measure a parameter relating to airflow during the rescue inhalation. The system further comprises a processor (14) configured to determine a number of the rescue inhalations during a first time period, and receive the parameter measured for at least some of the rescue inhalations. The processor determines, using a weighted model, the probability of the asthma exacerbation based on the number of rescue inhalations and the parameters. The model is weighted such that the number of rescue inhalations is more significant in the probability determination than the parameters.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/08 - Measuring devices for evaluating the respiratory organs
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
An inhaler housing (14) for an inhaler (10) for inhaling inhalable substances, the inhaler having: a body (14) and a dose counter (24) with a return spring (28), wherein a distinct guide surface (162) is provided for guiding the end of the return spring into a recess (152), the distinct guide surface being wider than an entrance mouth (160) of the recess, a dose counter chamber (22) being provided which is separated from a tubular interior space (182) of the inhaler by a barrier (180), the barrier including a stepped upper wall area (184) including at least three steps (186, 188, 190, 192) at different levels, the inhaler having a valve stem block (62) having an inner bore and a valve stem block having a seal (224) in the inner bore with a second diameter which is smaller than a first diameter of the inner bore, the inhaler having a canister (150) being adapted to move during operation between 1 and 4 mm, a drive being arranged to apply a firing force of between 15N and 60N of force to the canister at a position of the canister relative to a valve stem (54) at which the canister fires.
A61P 11/00 - Drugs for disorders of the respiratory system
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 9/00 - Medicinal preparations characterised by special physical form
68.
Application of raman spectroscopy for the manufacture of inhalation powders
The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
An inhaler may include a housing that comprises a mouthpiece, a medication canister, and an airflow channel formed between an air inlet and the mouthpiece. The inhaler may also include a pressure sensor configured to measure pressure (e.g., or alternatively, an acoustic sensor to measure acoustic sound waves). The pressure sensor may be attached to the medicament canister of the inhaler. The pressure sensor may be configured to be in a first position relative to the airflow channel when the medication canister is not actuated, and in a second position relative to the airflow channel when the medication canister is in an actuated position. The inhaler may also include a processor that is configured to receive pressure measurements from the pressure sensor, and detect whether an inhalation occurs prior the medication canister being depressed to release medication based on the pressure measurements (e.g, only the pressure measurements).
Provided is a system (10) for determining a probability of a CORD exacerbation in a subject. The system comprises a first inhaler (100) for delivering a rescue medicament to the subject. The rescue medicament may be suitable for treating the subject's acute respiratory disease, for example by effecting rapid dilation of the bronchi and bronchioles upon inhalation of the medicament. The first inhaler has a use-detection system (12B) configured to determine a rescue inhalation performed by the subject using the first inhaler. The system optionally includes a second inhaler for delivering a maintenance medicament to the subject during a routine inhalation A sensor system (12A) is configured to measure a parameter relating to airflow during the rescue inhalation and/or during the routine inhalation, when the second inhaler is included in the system. The system further comprises a processor (14) configured to determine a number of the rescue inhalations during a first time period, and receive the parameter measured for at least some of the rescue and/or routine inhalations. The processor then determines, using a weighted model, the probability of the CORD exacerbation based on the number of rescue inhalations and the parameters. The model is weighted such that the parameters are more significant in the probability determination than the number of rescue inhalations. Further provided is a method for determining the probability of a COPD exacerbation in a subject, which method employs the weighted model.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
An inhalation monitoring system includes an inhaler having a medicament delivery apparatus configured to deliver medicament to a user during an inhalation of the user; inhalation monitoring apparatus, configured to, during the inhalation, gather data for determining a measure of the user's lung function and/or lung health; and a processor configured to receive the data from the inhalation monitoring apparatus and, using the data, determine a measure of the user's lung function and/or lung health.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16Z 99/00 - Subject matter not provided for in other main groups of this subclass
A system may include a plurality of inhalers, where each inhaler comprising medicament, a processor, memory, and a transmitter, multiple processing modules that may reside at least partially on a user device, a digital health platform (DHP) that is configured to receive and aggregate inhaler data from inhalers that are associated with a plurality of different users and a plurality of different medicament types. The DHP may be configured to train a machine learning algorithm using training data via a supervised or an unsupervised learning method, wherein the training data comprises the time and the one or more inhalation parameters associated with each of the plurality of usage events. The DHP also configured to generate a compliance score, a future compliance score, and/or a risk score using the trained machine learning algorithm, and cause a display device to generate a notification indicating the score for the user.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
A device for delivering medication to a user may include a circular or elliptical body that include a mouthpiece, a flexible strip of medication, a lever, and a mouthpiece cover, where the mouthpiece cover is rotatable about the body. The electronics module may include a communication circuit, a sensor system, and a switch. The lever may be configured to actuate the switch when the lever is moved from a closed position to an open position. The lever is configured to advance a dose of medication on the flexible strip when moved from the closed position to the open position. When actuated, the switch may be configured to switch the electronics module from an off state to an active state wen the lever is actuated for a first time by a user. Thereafter, the electronics module is configured to not return to the off state.
A device for delivering medication to a user may include a circular or elliptical body that include a mouthpiece, a flexible strip of medication, a lever, and a mouthpiece cover, where the mouthpiece cover is rotatable about the body. The electronics module may include a communication circuit, a sensor system, and a switch. The lever may be configured to actuate the switch when the lever is moved from a closed position to an open position. The lever is configured to advance a dose of medication on the flexible strip when moved from the closed position to the open position. When actuated, the switch may be configured to switch the electronics module from an off state to an active state wen the lever is actuated for a first time by a user. Thereafter, the electronics module is configured to not return to the off state.
A system may include a plurality of inhalers, where each inhaler comprising medicament, a processor, memory, and a transmitter, multiple processing modules that may reside at least partially on a user device, a digital health platform (DHP) that is configured to receive and aggregate inhaler data from inhalers that are associated with a plurality of different users and a plurality of different medicament types. The DHP may be configured to train a machine learning algorithm using training data via a supervised or an unsupervised learning method, wherein the training data comprises the time and the one or more inhalation parameters associated with each of the plurality of usage events. The DHP also configured to generate a compliance score, a future compliance score, and/or a risk score using the trained machine learning algorithm, and cause a display device to generate a notification indicating the score for the user.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
76.
DRUG DELIVERY DEVICE WITH ELECTRONICS AND POWER MANAGEMENT
A system may limit the number of times an inhalation device transmits inhalation data to a single time to reduce the battery usage of the inhalation device. The system may include an inhalation device that has medicament and an electronics module. The system may limit the number of times the inhalation device transmits new inhalation data to any mobile device to a single time by causing the server to receive the new inhalation data from one of the mobile devices and causing the server to transmit the new inhalation data to other of the mobile devices prior to the other mobile devices transmitting a request for the new inhalation data to the inhalation device. The inhalation device may include a Quick Response (QR) code, and a mobile application may determine at least one of a medication type or a number of doses of the inhalation device from the QR code.
Provided is a system for providing an output for warning of a respiratory disease exacerbation in a subject. The system comprises a first inhaler for delivering a rescue medicament to the subject. The system optionally includes a second inhaler for delivering a maintenance medicament to the subject during a routine inhalation. A sensor system is configured to measure a parameter relating to airflow during the rescue inhalation and/or during the routine inhalation, when the second inhaler is included in the system. The system further comprises a processing module configured to monitor a frequency of the determined rescue inhalations. The processing module also monitors the parameter as a function of time. The processing module is further configured to provide the output for warning of a respiratory disease exacerbation if the parameter as a function of time is indicative of the lung condition of the subject deteriorating over a first time period, and the frequency of the determined rescue inhalations is higher during a second time period than during the first time period, the second time period being subsequent to the first time period. Further provided is a method for providing an output for warning of a respiratory disease exacerbation in a subject.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
78.
Inhalable formulation of fluticasone propionate and albuterol sulfate
This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.
A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
A61K 9/00 - Medicinal preparations characterised by special physical form
This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.
Provided is a system comprising an inhaler. The inhaler comprises a use determination system. The use determination system is configured to determine at least one first value of a usage parameter relating to use of the inhaler. A processing module is configured to receive the at least one first value. The processing module is also configured to receive a second value indicative of whether the subject is also suffering from a viral respiratory infection. The processing module then determines the level of acute risk based on the at least one first value and the second value. Also provided is a system for determining a probability that a subject having a chronic respiratory disease also has a severe acute respiratory syndrome. The system comprises a first inhaler for delivering a rescue medicament prescribed for the chronic respiratory disease. The first inhaler has a use determination system configured to determine a rescue inhalation performed by the subject using the first inhaler. The system optionally includes a second inhaler for delivering a maintenance medicament to the subject during a routine inhalation. A sensor system is configured to measure a parameter relating to airflow during the rescue inhalation and/or during the routine inhalation, when the second inhaler is included in the system. The system further comprises a processor configured to determine a number of the rescue inhalations during a first time period, and receive the parameter measured for at least some of the rescue and/or routine inhalations. The processor then determines the probability of the subject having the severe acute respiratory syndrome based on the number of rescue inhalations and the parameters. Further provided is a method for determining the probability of an asthma exacerbation in a subject, which method employs the weighted model.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
A system may include a plurality of inhalers, where each inhaler comprising medicament, a processor, memory, and a transmitter, multiple processing modules that may reside at least partially on a user device, a digital health platform (DHP) that is configured to receive and aggregate inhaler data from inhalers that are associated with a plurality of different users and a plurality of different medicament types. The DHP may determine a subset of the usage events based on the determined medication type, the determined time of day, and/or the determined date range. The DHP may determine a filtered list of users out of the plurality of users based on a comparison of the selected inhalation count threshold with the number of usage events that are associated with the same user and medication type.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
A system may include a plurality of inhalers, where each inhaler comprising medicament, a processor, memory, and a transmitter, multiple processing modules that may reside at least partially on a user device, a digital health platform (DHP) that is configured to receive and aggregate inhaler data from inhalers that are associated with a plurality of different users and a plurality of different medicament types. The DHP may determine a subset of the usage events based on the selected medication type, the selected time of day, and/or the selected date range. The DHP may determine a filtered list of users out of the plurality of users based on a comparison of the selected inhalation count threshold with the number of usage events that are associated with the same user and medication type.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
An inhalation monitoring system includes an inhaler having a medicament delivery apparatus configured to deliver medicament to a user during an inhalation of the user; inhalation monitoring apparatus, configured to, during the inhalation, gather data for determining a measure of the user's lung function and/or lung health; and a processor configured to receive the data from the inhalation monitoring apparatus and, using the data, determine a measure of the user's lung function and/or lung health.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16Z 99/00 - Subject matter not provided for in other main groups of this subclass
Provided is a system comprising an inhaler. The inhaler comprises a use determination system. The use determination system is configured to determine a parameter relating to airflow during a use of the inhaler by a subject. The use determination system also assigns a time to the use. The system also comprises a user interface, and a processing module. The processing module is configured to determine inhalation information from the parameter, and control the user interface to issue a notification that the inhalation information is available. The notification is issued at a notification time. The processing module is configured to implement a deliberate time delay such that the notification time is delayed relative to the time assigned to the use.
Provided is a system comprising an inhaler. The inhaler comprises a use determination system. The use determination system is configured to determine a parameter relating to airflow during a use of the inhaler by a subject. The use determination system also assigns a time to the use. The system also comprises a user interface, and a processing module. The processing module is configured to determine inhalation information from the parameter, and control the user interface to issue a notification that the inhalation information is available. The notification is issued at a notification time. The processing module is configured to implement a deliberate time delay such that the notification time is delayed relative to the time assigned to the use.
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61M 16/14 - Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
G06F 3/0488 - Interaction techniques based on graphical user interfaces [GUI] using specific features provided by the input device, e.g. functions controlled by the rotation of a mouse with dual sensing arrangements, or of the nature of the input device, e.g. tap gestures based on pressure sensed by a digitiser using a touch-screen or digitiser, e.g. input of commands through traced gestures
Provided is a system including a plurality of inhalers that each include a processor configured to determine a value of a usage parameter relating to use of the respective first inhaler, encrypt data based on the value, and transmit the encrypted data. At least two of the inhalers include different medicament, such as a rescue medicament and a maintenance medicament. The system includes an external device that includes a processor configured to distinguish between the encrypted data of each respective inhaler, determine respective usage information relating to each of the distinct types of medicament based on the respective encrypted data, and control a user interface (e.g., of the external device) to communicate the usage information related to each inhaler and/or each respective type of medicament.
A61M 11/02 - Sprayers or atomisers specially adapted for therapeutic purposes operated by air pressure applied to the liquid to be sprayed or atomised
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G06K 7/14 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation using light without selection of wavelength, e.g. sensing reflected white light
Provided is a blister pack for a dry powder inhaler, which dry powder inhaler is configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament. The first and second powder medicaments are contained within blister pockets (12A, 12B) defined in a strip (10). A series (11) of blister pockets is defined in the strip, which series extends linearly along the length of the strip. The first and second powder medicaments are contained in blister pockets, e.g. respective blister pockets, of the series. Alternatively or additionally, each of the blister pockets is elongated such as to have a largest dimension (20) parallel with the length of the strip. These measures, either individually or in combination, enable minimizing of the width of the strip in spite of the strip accommodating both the first and second powder medicaments. This, in turn, may enable the depth/thickness of the dry powder inhaler to be minimized, and/or additional space to be provided inside the dry powder inhaler for accommodating, for example, use detection and wireless connectivity electronics for sending use detection data to an external device, such as a smartphone.
Provided is a system comprising a plurality of inhalers that each include a processor configured to determine a value of a usage parameter relating to use of the respective first inhaler, encrypt data based on the value, and transmit the encrypted data. At least two of the inhalers include different medicament, such as a rescue medicament and a maintenance medicament. The system includes an external device that includes a processor configured to distinguish between the encrypted data of each respective inhaler, determine respective usage information relating to each of the distinct types of medicament based on the respective encrypted data, and control a user interface (e.g., of the external device) to communicate the usage information related to each inhaler and/or each respective type of medicament.
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
Provided is a blister pack for a dry powder inhaler configured to deliver a first powder medicament and a second powder medicament different from the first powder medicament. The first and second powder medicaments are contained within blister pockets defined in a strip. A series of blister pockets is defined in the strip, which series extends linearly along the length of the strip. The first and second powder medicaments are contained in blister pockets of the series. Alternatively or additionally, each of the blister pockets is elongated such as to have a largest dimension parallel with the length of the strip. These measures, either individually or in combination, enable minimizing of the width of the strip in spite of the strip accommodating both the first and second powder medicaments.
The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention generally relates to improved methods for the manufacture of inhalation powders. More particularly, aspects of the disclosure relate to methods for in-line monitoring of powder blending by Raman spectroscopy.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
G01N 21/85 - Investigating moving fluids or granular solids
The invention provides a method of testing an inhaler based on performing an optical analysis of a dry powder medicament plume discharged from the inhaler upon actuation. More particularly, embodiments of the invention comprise illuminating the dry powder plume with a source of electromagnetic radiation and capturing one or more images of a pattern of radiation reflected or diffracted by the illuminated plume. The images are subsequently processed to determine and/or analyse one or more geometric and/or dynamic characteristics of the plume.
Provided is a system comprising at least one inhaler. Each of the at least one inhaler comprises a use determination system configured to determine at least one value of a usage parameter relating to use of the respective inhaler by a subject. The system further comprises a user interface and a processing module. The user interface is configured to enable user-inputting of an indication of a status of a respiratory disease being experienced by the subject. The processing module is configured to control the user interface to issue a prompt to input the indication based on the at least one value.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
A compliance monitoring module for a breath-actuated inhaler comprising: a miniature pressure sensor, a sensor port of said sensor being pneumatically coupled to a flow channel through which a user can inhale; a processor configured to: receive a signal originating from a dosing mechanism of the inhaler indicating that medication has been released; receive data from a sensing element of the sensor; and based on said signal from said dosing mechanism and said data from said sensing element, make a determination that inhalation of a breath containing medication through said flow channel complies with one or more predetermined requirements for successful dosing; and a transmitter configured to, responsive to said determination, issue a dosing report.
A compliance monitoring module for an inhaler comprising: a miniature pressure sensor, a sensor port of said sensor being configured to be pneumatically coupled to a flow channel of said inhaler through which a user can inhale; a processor configured to: receive data from a sensing element of the pressure sensor; receive data from a mode sensor configured to detect when the inhaler changes from an inactive mode to an active mode; and based on said data from said pressure sensor sensing element and said data from said mode sensor, compile a compliance report; and a transmitter configured to issue said compliance report.
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
A breath actuated metered dose inhaler may comprise a canister fire system configured to fire a medicament containing canister in response to patient inhalation. The canister fire system may comprise a pneumatic force holding unit and having a rest configuration in which a metering valve of the canister is in a refill configuration; a prepared configuration in which a canister actuation force is retained by the pneumatic force holding unit and the canister fire system is actuatable by patient inhalation induced airflow; and a fire configuration in which the metering valve is in a dose delivery position. When in the prepared configuration, the force retained by the pneumatic force holding unit may be reduced by less than about 6% over a period of 5 minutes, preferably less than about 3% over a period of 5 minutes.
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
A61M 16/20 - Valves specially adapted to medical respiratory devices
An inhaler includes a main body having a canister housing, a medicament canister retained in a central outlet port of the canister housing, and a dose counter having an actuation member for operation by movement of the medicament canister. The canister housing has an inner wall, and a first inner wall canister support formation extending inwardly from a main surface of the inner wall. The canister housing has a longitudinal axis X which passes through the center of the central outlet port. The first inner wall canister support formation, the actuation member, and the central outlet port lie in a common plane coincident with the longitudinal axis X such that the first inner wall canister support formation protects against unwanted actuation of the dose counter by reducing rocking of the medicament canister relative to the main body of the inhaler.
A system may limit the number of times an inhalation device transmits inhalation data to a single time to reduce the battery usage of the inhalation device. The system may include an inhalation device that has medicament and an electronics module. The system may limit the number of times the inhalation device transmits new inhalation data to any mobile device to a single time by causing the server to receive the new inhalation data from one of the mobile devices and causing the server to transmit the new inhalation data to other of the mobile devices prior to the other mobile devices transmitting a request for the new inhalation data to the inhalation device. The inhalation device may include a Quick Response (QR) code, and a mobile application may determine at least one of a medication type or a number of doses of the inhalation device from the QR code.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
99.
Drug delivery device with electronics and power management
A system may limit the number of times an inhalation device transmits inhalation data to a single time to reduce the battery usage of the inhalation device. The system may include an inhalation device that has medicament and an electronics module. The system may limit the number of times the inhalation device transmits new inhalation data to any mobile device to a single time by causing the server to receive the new inhalation data from one of the mobile devices and causing the server to transmit the new inhalation data to other of the mobile devices prior to the other mobile devices transmitting a request for the new inhalation data to the inhalation device. The inhalation device may include a Quick Response (QR) code, and a mobile application may determine at least one of a medication type or a number of doses of the inhalation device from the QR code.
A system may include an external device and an inhaler. The external device may include a processor, a communication circuit, and memory. The inhaler may include a mouthpiece, medicament, a mechanical dose counter, and an electronics module comprising a processor and a communication circuit. The electronics module may record a dosing event when the inhaler is actuated, such as when the mouthpiece cover is opened, and send a signal indicating the dosing event to the external device. The external device may receive a mechanical dose reading of the mechanical dose counter, determine an electronic dose reading based on the signal indicating the dosing event, determine that a discrepancy between the mechanical dose reading and the electronic dose reading exceeds a threshold, and notify the user of the discrepancy, for example, by providing a notification to the user by way of a mobile application residing on the external device.
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
